12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A,
Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered
into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Blood. 1998 Oct 1;92(7):2322-33.
.
Harousseau, J.L., Pignon, B., Witz, F., Polin, V., Tellier, Z., Hurteloup, P., and Cahn, J.Y. Treatment of acute
myeloblastic leukemia in adults. The GOELAM experience. Hematol Cell Ther., 38 : 381-391, 1996.
Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R,
Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R;
EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the
treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission
(CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
Blood. 2003 Aug 15;102(4):1232-40.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission
therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group
Study. Blood. 2000 Dec 15;96(13):4075-83.
K. Wheatley, A. K. Burnett, A. H. Goldstone, R. G. Gray, I. M. Hann, C. J. Harrison, J. K. Rees, R. F. Stevens,
and H. Walker. A simple, robust, validated and highly predictive index for the determination of risk-directed
therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research
Council's Adult and Childhood Leukaemia Working Parties. Br.J.Haematol. 107 (1):69-79, 1999.
Zittoun, R.A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G.,
and Papa, G. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in
acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the
Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups [see
comments]. N.Engl.J.Med., 332: 217-223, 1995.
AML 1. CR registerdata
Ferrant, A., Labopin, M., Frassoni, F., Prentice, H.G., Cahn, J.Y., Blaise, D., Reiffers, J., Visani, G., Sanz, M.A.,
Boogaerts, M.A., Lowenberg, B., and Gorin, N.C. Karyotype in acute myeloblastic leukemia: prognostic
significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow
Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow
Transplantation (EBMT). Blood, 90: 2931-2938, 1997.
Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D, Keating A, Gale RP, Geller RB,
Laughlin MJ, Lazarus HM, Luger SM, McCarthy PL, Rowe JM, Saez RA, Vowels MR, Horowitz MM. Effect of
postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute
32